Statute
BPCIA
102 published works
Big Molecule Watch
Regeneron Sues Formycon AG for Proposed Biosimilar of EYLEA in West Virginia District Court
Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed a Complaint on November 29, 2023, against Formycon AG (“Formycon”) in the U.S. District Court for the Northern District of West Virginia, alleging infringement of…
Biosimilars Law Bulletin
New BPCIA Case Filed: Genentech and Biogen Want to Stop Dr. Reddy’s Rituximab Biosimilar from Entering the U.S. Market
On November 17, 2023, Genentech, Hoffman-La Roche, and Biogen (collectively “plaintiffs”) filed a complaint in the federal district court for the District of New Jersey against Dr. Reddy’s Laboratories and…
Big Molecule Watch
Regeneron Sues Samsung Bioepis for Proposed Biosimilar of EYLEA in West Virginia District Court
By Yoko Bian
Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed a Complaint on November 22 against Samsung Bioepis Co., Ltd. (“Bioepis”) in the U.S. District Court for the Northern District of West Virginia, alleging infringement…
Big Molecule Watch
Genentech, Roche, and Biogen Sue Dr. Reddy’s and Fresenius for a Proposed Biosimilar of Rituxan in District of New Jersey
Genentech, Roche, and Biogen filed a Complaint on November 17 against Dr. Reddy’s Laboratories (“DRL”) and Fresenius in the U.S. District Court for the District of New Jersey, alleging infringement of…
Big Molecule Watch
Biosimilars Patent Challenges at the PTAB: Update and Lessons Learned
On November 14, 2023, in the third webinar in Goodwin’s 2023 Biosimilars Webinar Series, Goodwin IP Litigation partner and managing editor of the Goodwin PTAB Trial Tracker newsletter, Linnea Cipriano,…
Big Molecule Watch
Genentech and Biogen File Joint Stipulation of Dismissal in BPCIA Litigation Regarding Tocilizumab
By Sam Herron
As we previously reported, in July 2023 Genentech, Inc., Hoffmann-LaRoche, Inc., and Chugai Pharmaceutical Co., Ltd. (collectively, “Genentech”) filed BPCIA litigation against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in…
Big Molecule Watch
Patent Dance Disclosures and Beyond: Recent Biosimilars Litigation at the District Court
The world of biosimilar litigation is back in full swing with several BPCIA lawsuits currently pending. On October 12, 2023, in the second webinar in Goodwin’s 2023 Biosimilars Webinar Series,…
Big Molecule Watch
Update: Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Case Now Complete
We previously reported on the opening post-trial briefs in Regeneron’s BPCIA case against Mylan and Biocon (who was added as a defendant after the original defendant, Mylan, transferred its rights…
Big Molecule Watch
Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumab
By Elaine Blais
Yesterday, Genentech, Inc., Hoffmann-LaRoche, Inc., and Chugai Pharmaceutical Co., Ltd. (“Genentech”) filed BPCIA litigation against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the District of Massachusetts. In its Complaint,…
Big Molecule Watch
Court Denies Motion for Preliminary Injunction in Biogen v. Sandoz Natalizumab BPCIA Litigation
As we previously reported, Biogen sued Sandoz and Polpharma (“Defendants”) in a BPCIA litigation related to Defendants’ natalizumab biosimilar. On October 19, 2022, Biogen filed a Motion for Preliminary Injunction…